These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 23740622)

  • 21. A quantitative approach to benefit-risk assessment of medicines - part 2: the practical application of a new model.
    Mussen F; Salek S; Walker S; Phillips L
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S16-41. PubMed ID: 17546574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives.
    Felli JC; Noel RA; Cavazzoni PA
    Med Decis Making; 2009; 29(1):104-15. PubMed ID: 18812582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 24. WHO expert committee on specifications for pharmaceutical preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2013; (981):i-xi, 1-188. PubMed ID: 23821930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug quality in South Africa: perceptions of key players involved in medicines distribution.
    Patel A; Norris P; Gauld R; Rades T
    Int J Health Care Qual Assur; 2009; 22(5):547-60. PubMed ID: 19725374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of Regulatory Decision-Making Practices: Issues Facing Companies and Agencies.
    Bujar M; McAuslane N; Salek S; Walker S
    Ther Innov Regul Sci; 2016 Jul; 50(4):487-495. PubMed ID: 30227024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives.
    Donelan R; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):319-28. PubMed ID: 25628072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.
    Eichler HG; Pignatti F; Flamion B; Leufkens H; Breckenridge A
    Nat Rev Drug Discov; 2008 Oct; 7(10):818-26. PubMed ID: 18787530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.
    Borup R; Traulsen JM; Kaae S
    Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
    Smirniotopoulos A
    Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians.
    Quartey G; Wang J
    Pharm Stat; 2012; 11(1):82-5. PubMed ID: 21997832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.
    Mt-Isa S; Hallgreen CE; Wang N; Callréus T; Genov G; Hirsch I; Hobbiger SF; Hockley KS; Luciani D; Phillips LD; Quartey G; Sarac SB; Stoeckert I; Tzoulaki I; Micaleff A; Ashby D;
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):667-78. PubMed ID: 24821575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommendations for benefit-risk assessment methodologies and visual representations.
    Hughes D; Waddingham E; Mt-Isa S; Goginsky A; Chan E; Downey GF; Hallgreen CE; Hockley KS; Juhaeri J; Lieftucht A; Metcalf MA; Noel RA; Phillips LD; Ashby D; Micaleff A;
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):251-62. PubMed ID: 26800458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies.
    Tubach F; Lamarque-Garnier V; Castot A;
    Therapie; 2011; 66(4):355-62, 347-54. PubMed ID: 21851800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.
    Brett Hauber A; Fairchild AO; Reed Johnson F
    Appl Health Econ Health Policy; 2013 Aug; 11(4):319-29. PubMed ID: 23637054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Key Opinion Leaders' Interviews to Inform the Future of Benefit-Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations.
    Simonetti A; Colilla S; Edwards B; Kübler J; Lackey L; Rodriguez L; Talbot S; Yang H; Wang W; Williams D; Higginson JM
    Drug Saf; 2024 Sep; 47(9):853-868. PubMed ID: 38824267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
    Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
    Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.